Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: aul c. Semin Hematol. 1991 Jul;28(3 Suppl 4):35-8. Semin Hematol. 1991. PMID: 1780750 Clinical Trial. No abstract available.
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Hiddemann W, Schleyer E, Uhrmeister C, Aul CH, Maschmeyer G, Heinecke A, Büchner T. Hiddemann W, et al. Among authors: aul ch. Cancer Treat Rev. 1990 Sep;17(2-3):279-85. doi: 10.1016/0305-7372(90)90058-n. Cancer Treat Rev. 1990. PMID: 2272043 Clinical Trial.
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Hiddemann W, Aul C, Maschmeyer G, Lathan B, Köppler H, Hoffmann R, Grüneisen T, Donhuijsen-Ant R, Ludwig WD, Balleisen L, et al. Hiddemann W, et al. Among authors: aul c. Onkologie. 1989 Feb;12(1):4-6. doi: 10.1159/000216586. Onkologie. 1989. PMID: 2654790 Clinical Trial.
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: aul c. Leuk Lymphoma. 1993;10 Suppl:133-7. doi: 10.3109/10428199309149125. Leuk Lymphoma. 1993. PMID: 8481662 Clinical Trial.
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Büchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel TH, Gramatzki M, Diedrich H, Kolbe K, Fuhr HG, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Gökbuget N, Völkers B, Messerer D, Uberla K. Hoelzer D, et al. Among authors: aul c. Blood. 1996 Jan 15;87(2):495-508. Blood. 1996. PMID: 8555471 Free article.
260 results